Akebia board recommends shareholders vote for merger with Keryx.
Akebia Therapeutic mailed a letter in connection with the special meeting of Akebia (AKBA) shareholders that has been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx Biopharmaceuticals (KERX). The Akebia Board of Directors unanimously recommends that Akebia shareholders vote "FOR" the proposals relating to the proposed merger with Keryx. In a letter, the board states: "The Special Meeting to approve our proposed merger with Keryx is approaching. The Board unanimously believes this combination will provide substantial strategic, financial and operational benefits to Akebia, and increase the long-term value of Akebia. We came to this conclusion following a robust strategic evaluation. This included considering the advice of our independent financial advisors, Evercore and J.P. Morgan. Accordingly, we recommend that shareholders vote today "FOR" the Akebia proposals set forth in the definitive proxy statement, including "FOR" the proposal to issue shares of Akebia common stock to Keryx shareholders in relation to the proposed merger. Notably, we have talked with numerous shareholders and key opinion leaders who support the actions we are taking. Importantly, several independent research analysts are equally supportive."
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 13, 2018|
|Previous Article:||National General to acquire National Farmers Union Insurance.|
|Next Article:||Cardiovascular Systems says first patients in Europe treated with Peripheral OAS.|